Eli Lilly's Employer Connect: Unlocking GLP-1 Demand

Eli Lilly and Company (NYSE: LLY), the world's most valuable pharmaceutical stock, continues to lead the GLP-1 market for weight-loss and diabetes treatments. In its most recent earnings report, Lilly forecasted robust 25% growth for 2026, surpassing expectations despite being slower than the 45% growth in 2025. This would mark the company's third-highest annual growth rate in history, driven by strong sales from its GLP-1 franchises like Zepbound.

GLP-1 receptor agonists like Zepbound (tirzepatide) mimic gut hormones to regulate blood sugar, slow gastric emptying, and reduce appetite, making them essential for managing type 2 diabetes and obesity. While growth rates can't stay sky-high indefinitely, Lilly's strategies position it far ahead of competitor Novo Nordisk (NYSE: NVO), which anticipates a 5% to 13% revenue drop in 2026—its worst in years. In U.S. dollars, Novo hasn't seen more than a 5% decline since 2014, and in Danish Kroner, not since 1998.

Eli Lilly's Dominant Position in the Injectable GLP-1 Market

This contrast highlights Lilly's superior stance in injectable GLP-1s. Zepbound and Mounjaro have captured significant market share due to their dual GLP-1/GIP action, offering enhanced weight loss and glycemic control compared to single-agonist options like Ozempic or Wegovy (semaglutide). Patients with obesity or type 2 diabetes often benefit from these therapies, which can lead to 15-20% body weight reduction in clinical use, alongside cardiovascular risk improvements.

However, access barriers persist. Lilly is actively expanding drug availability and advancing oral GLP-1 options to sustain momentum. These efforts address real-world challenges: high out-of-pocket costs deter many patients, limiting adherence to these transformative metabolic therapies.

Employer Connect: Lilly's Strategy to Bridge the Obesity Coverage Gap

One of Lilly's boldest moves is the launch of its Employer Connect platform, aimed at filling the massive gap in employer-sponsored obesity care. Lilly notes that approximately half of people on employer-sponsored plans lack coverage for obesity treatments. A survey revealed that only 20% of companies with over 200 workers cover weight-loss drugs, rising slightly to 43% for those with 5,000+ employees.

How Employer Connect Works and Its Pricing Advantage

This untapped market represents huge potential for Zepbound. Through LillyDirect, the direct-to-consumer platform, Zepbound costs $299 to $449 per month out-of-pocket—far below the list price of over $1,000, but still prohibitive for many. Employer Connect changes this by offering Zepbound to employers at a discounted $449 per month, with employees paying just a fraction.

Crucially, the program bypasses traditional pharmacy benefit managers (PBMs), which act as middlemen with opaque pricing and concentrated market power. Instead, employers select from over 15 independent program administrators, fostering competition based on services like telehealth integration or adherence support. For patients, this means easier access to GLP-1 therapy, potentially improving outcomes in metabolic health.

Patient Benefits and Considerations

Improved employer coverage could dramatically increase GLP-1 utilization. Patients starting Zepbound should discuss with their doctor monitoring for common side effects like nausea or gastrointestinal issues, which often improve over time. Tools like Shotlee can help track symptoms, dosages, and progress during the initial weeks. While adoption may ramp up into 2027 as employers evaluate, even existing Zepbound-covered plans switching could boost volume, offsetting any short-term pricing pressure.

Lilly's Oral GLP-1 Advance: Orforglipron Beats Rybelsus in Head-to-Head Trial

In parallel, Lilly announced promising data on its developmental oral GLP-1, orforglipron. In a head-to-head trial against Novo's approved oral GLP-1, oral semaglutide (Rybelsus), orforglipron demonstrated superior efficacy for type 2 diabetes patients.

Key Trial Results: A1C Reduction and Weight Loss

• A1C fell by 2.2% with orforglipron vs. 1.4% with oral semaglutide.
• Weight loss was 9.2% with orforglipron vs. 5.3% with oral semaglutide.

These results position orforglipron for potential approval in type 2 diabetes, where Rybelsus has been available since 2019. Though the oral type 2 diabetes market is smaller—Rybelsus generated $3.5 billion in 2025 sales, about one-tenth of Novo's combined $32.5 billion from Ozempic and Wegovy—Lilly eyes a larger obesity indication. Oral options appeal to injection-averse patients, offering daily pills with similar GLP-1 benefits: appetite suppression and glucose control without needles.

Safety profiles align with class effects; clinical background emphasizes gradual titration to minimize GI side effects. Compared to injectables, orals may enhance adherence for long-term metabolic management.

Broader Implications for GLP-1 Access and Growth

Lilly's innovations—expanding access via Employer Connect and pioneering orals like orforglipron—open new doors for GLP-1 demand. While the company has ballooned into a giant, its track record of 25% growth and innovation makes it resilient. For patients, these moves mean more affordable paths to therapies that address obesity and diabetes at their roots.

Comparing Lilly's GLP-1 Portfolio

Patients weighing options should consult providers; GLP-1s aren't for everyone and require lifestyle integration.

Key Takeaways for Patients and Providers

• Lilly's Employer Connect targets the 50% coverage gap, offering Zepbound at $449/month to employers.
• Orforglipron's trial win: 2.2% A1C drop and 9.2% weight loss outperform Rybelsus.
• These strategies could drive GLP-1 adoption, improving metabolic health outcomes.
• Discuss employer benefits and trial eligibility with your doctor for personalized access.

In conclusion, Eli Lilly's Employer Connect and orforglipron advancements signal sustained GLP-1 momentum, enhancing patient access while fueling business growth. Stay informed on coverage changes to optimize your metabolic health journey.